High dose intermittent ticarcillin–clavulanate administration in pediatric cystic fibrosis patients

Zobell, Jeffery T.; Ampofo, Krow; Cash, Jared; Korgenski, Kent; Chatfield, Barbara A.

doi:10.1016/j.jcf.2010.04.003

« Previous Next »Journal of Cystic Fibrosis
Volume 9, Issue 4 , Pages 280-283, July 2010

High dose intermittent ticarcillin–clavulanate administration in pediatric cystic fibrosis patients

Jeffery T. Zobell
- Pharmacy, Intermountain Primary Children's Medical Center, 100 North Mario Capecchi Drive, Salt Lake City, UT, 84113, United States
- Intermountain Cystic Fibrosis Pediatric Center, 100 North Mario Capecchi Drive, Salt Lake City, UT, 84113, United States
- Corresponding author. 100 North Mario Capecchi Drive, Salt Lake City, UT 84113, United States. Tel.: +1 801 662 2641; fax: +1 801 662 2622.
Krow Ampofo
- Division of Infectious Disease, University of Utah, PO Box 581289, Salt Lake City, UT 84132, United States
Jared Cash
- Pharmacy, Intermountain Primary Children's Medical Center, 100 North Mario Capecchi Drive, Salt Lake City, UT, 84113, United States
Kent Korgenski
- Division of Infectious Disease, University of Utah, PO Box 581289, Salt Lake City, UT 84132, United States
- Microbiology, Intermountain Healthcare, 100 North Mario Capecchi Drive, Salt Lake City, UT, 84113, United States
Barbara A. Chatfield
- Intermountain Cystic Fibrosis Pediatric Center, 100 North Mario Capecchi Drive, Salt Lake City, UT, 84113, United States

Received 26 February 2010; received in revised form 17 April 2010; accepted 20 April 2010.

Abstract

Background

The Intermountain Cystic Fibrosis Pediatric Center utilizes ticarcillin–clavulanate 400mg/kg/day divided every 6h, (maximum 24g/day). This dosing strategy is higher than the Cystic Fibrosis Foundation (CFF) recommendations and the Food and Drug Administration (FDA) approved package labeling. The purpose is to determine the safety of this dosing regimen.

Methods

A retrospective study of pediatric cystic fibrosis (CF) patients admitted from January 1, 2005 to December 31, 2009 who received the dosing regimen for at least 7days. Baseline and follow-up laboratory parameters were recorded. Statistical analysis was performed.

Results

127 patients met inclusion criteria. The mean (±SD) ticarcillin dose was 3.5g (±2.16) every 6h; while the mean (±SD) total ticarcillin dose was 13.5g (±6.5) per day. No significant differences occurred in liver function tests, white blood count, and platelet count from baseline. Serum creatinine showed a statistically significant decrease from baseline.